2-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]acetic acid | 948022-57-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]acetic acid
• CAS: 948022-57-9
• 化学式: C₁₄H₁₆F₃NO₂
• 分子量: 287.282
• InChiKey: GGFJLCPDBIUMDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]acetic acid 在 盐酸 、 4-二甲氨基吡啶 、 水 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 2.27h， 生成 N-(5-hydroxypyridin-2-yl)-2-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]acetamide
  参考文献：
  名称：

  [EN] INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
  [FR] INHIBITEURS DE DIHYDROCÉRAMIDE DÉSATURASE POUR LE TRAITEMENT DE MALADIES

  摘要：

  本文披露了二氢神经酰胺脱饱和酶1（Des1）抑制剂化合物和组合物，这些化合物在治疗疾病方面非常有用，如代谢性疾病、心血管疾病、纤维化疾病、自身免疫/慢性炎症性疾病、囊性纤维化、各种癌症、神经退行性疾病、脂质储存障碍和缺血/再灌注损伤，预期通过抑制Des1对患者具有治疗作用。还提供了在人类或动物受试者中抑制Des1活性的方法。

  公开号：

  WO2018112077A1
• 作为产物：
  描述：

  4-派啶乙酸甲酯 在 tris-(dibenzylideneacetone)dipalladium(0) 、 水 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 、 lithium hydroxide 、 sodium t-butanolate 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 18.0h， 生成 2-[1-[4-(trifluoromethyl)phenyl]piperidin-4-yl]acetic acid
  参考文献：
  名称：

  [EN] INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
  [FR] INHIBITEURS DE DIHYDROCÉRAMIDE DÉSATURASE POUR LE TRAITEMENT DE MALADIES

  摘要：

  本文披露了二氢神经酰胺脱饱和酶1（Des1）抑制剂化合物和组合物，这些化合物在治疗疾病方面非常有用，如代谢性疾病、心血管疾病、纤维化疾病、自身免疫/慢性炎症性疾病、囊性纤维化、各种癌症、神经退行性疾病、脂质储存障碍和缺血/再灌注损伤，预期通过抑制Des1对患者具有治疗作用。还提供了在人类或动物受试者中抑制Des1活性的方法。

  公开号：

  WO2018112077A1

文献信息

• NIROGENOUS HETEROCYCLIC DERIVATIVES SUBSTITUTED WITH CYCLIC GROUPS
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1988077A1

  公开（公告）日：2008-11-05

  It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. A compound represented by: wherein Z is N or CR1, A1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R1, R2, Ra, Rb, Rc and Rd are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is -(CR3R4)m-, -CO(CR3R4)n-, -CONR5(CR3R4)n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R3 and R4 are each independently hydrogen, halogen, hydroxy etc., and R5 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or a solvate thereof.

  研究发现，由式（I）代表的含氮杂环衍生物能与 NR1/NR2B 受体特异性结合，可用作 NR2B 受体拮抗剂。 由式（I）代表的化合物 其中 Z 是 N 或 CR1，A1 是任选被取代的含氮芳香族单环基团、任选被取代的含氮芳香族融合环基团等，A2 是芳香烃环基团或芳香杂环基团，各自任选具有一个取代基，R1、R2、Ra、Rb、Rc 和 Rd 各自独立地是氢、羟基等、w 是 2 或 3，t 是 1 或 2，X 是-(CR3R4)m-、-CO(CR3R4)n-、-CONR5(CR3R4)n- 等，m 是 1 至 4 的整数，n 是 0 至 4 的整数，R3 和 R4 各自独立地是氢、卤素、羟基等，R5 是氢或低级烷基、 或其药学上可接受的盐或溶液。
• Inhibitors of dihydroceramide desaturase for treating disease
  申请人：Centaurus Therapeutics

  公开号：US11135207B2

  公开（公告）日：2021-10-05

  Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.

  本公开涉及二氢神经酰胺脱饱和酶1（Des1）抑制剂化合物和组合物，这些化合物和组合物在治疗某些疾病（例如代谢性疾病、心血管疾病、纤维化疾病、自身免疫性疾病/慢性炎症性疾病、囊性纤维化、多种癌症、神经退行性疾病、脂质沉积障碍及缺血/再灌注损伤）时是有用的，且预期对于患者而言Des1的抑制具有治疗作用。本发明还提供了抑制人类或动物受试者Des1活性的方法。
• EP1988077
  申请人：——

  公开号：——

  公开（公告）日：——
• NITROGEN-CONTAINING HETEROCYCLE DERIVATIVES SUBSTITUTED WITH CYCLIC GROUP
  申请人：Masui Moriyasu

  公开号：US20090062261A1

  公开（公告）日：2009-03-05

  It was found out that the nitrogen-containing heterocyclic derivative represented by the formula (I) specifically binds to a receptor of NR1/NR2B, and is used as a NR2B receptor antagonist. A compound represented by: wherein Z is N or CR 1 , A 1 is a nitrogen-containing aromatic monocyclic group which is optionally substituted, a nitrogen-containing aromatic fused cyclic group which is optionally substituted etc., A 2 is an aromatic hydrocarbon cyclic group or an aromatic heterocyclic group, each optionally having a substituent, R 1 , R 2 , R a , R b , R c and R d are each independently hydrogen, hydroxy, etc., w is 2 or 3, t is 1 or 2, X is —(CR 3 R 4 )m-, —CO(CR 3 R 4 )n-, —CONR 5 (CR 3 R 4 )n- etc., m is an integer of 1 to 4, n is an integer of 0 to 4, R 3 and R 4 are each independently hydrogen, halogen, hydroxy etc., and R 5 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, or a solvate thereof.
• INHIBITORS OF DIHYDROCERAMIDE DESATURASE FOR TREATING DISEASE
  申请人：Centaurus Therapeutics

  公开号：US20190328720A1

  公开（公告）日：2019-10-31

  Disclosed herein are dihydroceramide desaturase 1 (Des1) inhibitor compounds and compositions, which are useful in the treatment of diseases, such as metabolic, cardiovascular, fibrotic, autoimmune/chronic inflammatory diseases, cystic fibrosis, various cancers, neurodegenerative diseases, lipid storage disorders, and ischemia/reperfusion injury, where inhibition of Des1 is expected to be therapeutic to a patient. Methods of inhibition of Des1 activity in a human or animal subject are also provided.